Search research articles
Contact Us
Filters
Showing results (1-10 of 323) with videos related to
Page
of 33
Sort By:
Journal of Psoriasis and Psoriatic Arthritis
|
September 19, 2024
Resident Memory T Cells in Psoriasis: Key to a Cure?
Andrew Blauvelt
Expert Opinion on Biological Therapy
|
December 16, 2015
Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis
Andrew Blauvelt
JAMA Dermatology
|
February 14, 2024
Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis
Andrew Blauvelt
Expert Opinion on Drug Safety
|
August 23, 2016
Safety of secukinumab in the treatment of psoriasis
Andrew Blauvelt
JAMA Dermatology
|
September 19, 2019
Predicting Clinical Responses to Ustekinumab: Progress Toward a Future of Personalized Medicine
Andrew Blauvelt
The Journal of Investigative Dermatology
|
February 26, 2017
IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis
Andrew Blauvelt
The Journal of Investigative Dermatology
|
April 15, 2008
T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis
Andrew Blauvelt
The Journal of Investigative Dermatology
|
August 23, 2002
Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease
Vincent Piguet, Andrew Blauvelt
Journal of the American Academy of Dermatology
|
January 17, 2004
Rapid publication for selected JAAD articles
Andrew Blauvelt, Jeffrey Bernhard
Clinical Reviews in Allergy & Immunology
|
August 16, 2018
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Page
of 33
Search research articles
Search
Showing results (1-10 of 323) with videos related to
Sort By:
Page
of 33
Journal of Psoriasis and Psoriatic Arthritis
|
September 19, 2024
Resident Memory T Cells in Psoriasis: Key to a Cure?
Andrew Blauvelt
Expert Opinion on Biological Therapy
|
December 16, 2015
Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis
Andrew Blauvelt
JAMA Dermatology
|
February 14, 2024
Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis
Andrew Blauvelt
Expert Opinion on Drug Safety
|
August 23, 2016
Safety of secukinumab in the treatment of psoriasis
Andrew Blauvelt
JAMA Dermatology
|
September 19, 2019
Predicting Clinical Responses to Ustekinumab: Progress Toward a Future of Personalized Medicine
Andrew Blauvelt
The Journal of Investigative Dermatology
|
February 26, 2017
IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis
Andrew Blauvelt
The Journal of Investigative Dermatology
|
April 15, 2008
T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis
Andrew Blauvelt
The Journal of Investigative Dermatology
|
August 23, 2002
Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease
Vincent Piguet, Andrew Blauvelt
Journal of the American Academy of Dermatology
|
January 17, 2004
Rapid publication for selected JAAD articles
Andrew Blauvelt, Jeffrey Bernhard
Clinical Reviews in Allergy & Immunology
|
August 16, 2018
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Page
of 33